Neuronetics Inc
STIM2.520USD
-0.220-8.03%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
172.48MMarket Cap
LossP/E TTM
More Details of Neuronetics Inc Company
Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment for people suffering from neurohealth conditions. In addition to selling the NeuroStar system and associated treatment sessions to customers, it operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or TMS) and Spravato (esketamine nasal spray) for the treatment of major depressive disorder (MDD) and other mental health disorders. NeuroStar Advanced Therapy is the TMS treatment for MDD in adults. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. It provides more than 1.68 million treatments to over 51,000 patients struggling with depression.
Neuronetics Inc Info
Ticker SymbolSTIM
Company nameNeuronetics Inc
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Number of employees716
Security typeOrdinary Share
Fiscal year-endJun 28
Address3222 Phoenixville Pike
CityMALVERN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code19355
Phone18776007555
Websitehttps://neurostar.com/neuronetics/
Ticker SymbolSTIM
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Company Executives of Neuronetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
By RegionUSD
Name
Revenue
Proportion
United States
37.66M
98.81%
International
452.00K
1.19%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
30.28%
The Vanguard Group, Inc.
4.00%
BlackRock Institutional Trust Company, N.A.
2.99%
Cucuz (Sasha)
2.97%
Sullivan (Keith J)
2.35%
Other
57.41%
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
30.28%
The Vanguard Group, Inc.
4.00%
BlackRock Institutional Trust Company, N.A.
2.99%
Cucuz (Sasha)
2.97%
Sullivan (Keith J)
2.35%
Other
57.41%
Shareholder Types
Shareholders
Proportion
Private Equity
31.36%
Hedge Fund
10.96%
Investment Advisor
9.91%
Individual Investor
9.48%
Investment Advisor/Hedge Fund
4.83%
Research Firm
1.83%
Bank and Trust
0.10%
Pension Fund
0.07%
Other
31.47%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
196
39.02M
59.02%
-13.74M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
2023Q2
222
21.10M
73.37%
-11.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madryn Asset Management, LP
20.74M
31.36%
-3.50M
-14.44%
Aug 08, 2025
The Vanguard Group, Inc.
2.74M
4.15%
+436.54K
+18.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.05M
3.1%
+1.67M
+440.36%
Jun 30, 2025
Cucuz (Sasha)
2.02M
3.06%
+30.00K
+1.50%
May 22, 2025
Sullivan (Keith J)
1.61M
2.43%
--
--
Mar 24, 2025
Balyasny Asset Management LP
1.51M
2.28%
+92.05K
+6.50%
Jun 30, 2025
Ikarian Capital LLC
1.10M
1.66%
-300.00
-0.03%
Jun 30, 2025
Masters Capital Management, L.L.C.
1.00M
1.51%
--
--
Jun 30, 2025
Manatuck Hill Partners, LLC
920.00K
1.39%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
879.04K
1.33%
+556.27K
+172.34%
Jun 30, 2025
View more
Related ETFs
Updated: 21 hours ago
Updated: 21 hours ago
Name
Proportion
AdvisorShares Psychedelics ETF
3.78%
Invesco NASDAQ Future Gen 200 ETF
0.4%
iShares Neuroscience and Healthcare ETF
0.2%
Vanguard US Momentum Factor ETF
0.06%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
View more
AdvisorShares Psychedelics ETF
Proportion3.78%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.4%
iShares Neuroscience and Healthcare ETF
Proportion0.2%
Vanguard US Momentum Factor ETF
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
